Function: using CRISPR to match patients to treatments

Function Oncology is using its CRISPR-based functional genomics platform to help physicians select the right treatments for cancer patients, and drug developers identify new targets. The company launched on April 12 with a $28 million series A financing led by Andreessen Horowitz and Section 32.

CEO Srinath Sampath told BioCentury he was inspired to start Function Oncology Inc. by the outliers in waterfall plots used to report the results of Phase I and II cancer trials. ...